Grant: Operating Grant: ECI grants in Maternal, Reproductive, Child & Youth Health
University of Calgary
$104,996.00
A prospective study evaluating complement activation among pregnant patients with obstetrical antiphospholipid syndrome
FY 2019-20
Summary
Antiphospholipid syndrome (APS) is an autoimmune disease that can lead to blood clots (thrombosis) or complications in pregnancy such as pregnancy loss, pre-eclampsia or intrauterine growth restriction because of placental insufficiency. The cause of APS is poorly understood, and there is a high rate of pregnancy loss despite standard blood thinner injections and aspirin given during pregnancy. The complement system is a network of proteins and is an important part of the immune system. There is growing evidence that changes to the complement system may play a central role in what causes APS. By better understanding complement activation and which complement proteins are abnormal in pregnant patients with APS, we can research targeted therapies to improve pregnancy outcomes for women with APS.
Researchers at Johns Hopkins University have recently developed a blood test (the modified Ham test) that can detect complement activation in patients. They have already shown that there is complement activation in a related pregnancy complication called HELLP syndrome (Hemolysis, Elevated Liver enzymes, Low Platelets), and that complement activation was present before any clinical evidence of HELLP syndrome started.
The aim of our study is to assess if there is complement activation in pregnant patients with APS using the modified Ham test and other complement studies, compared to healthy pregnant women, and if this is related to pregnancy complications. We will also test if there are genetic mutations in complement genes.
We will follow pregnant patients with and without APS throughout pregnancy. We will test for complement activation with monthly blood tests until the third trimester, and then every 2 weeks until delivery. By collecting this information over time, we will determine if there is an association with the development of pregnancy complications, and if we can identify changes in complement before those complications happen.
Department
Program
Operating Grant: ECI grants in Maternal, Reproductive, Child & Youth Health
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
405079
Name
Skeith Leslie
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Clinical
Prcname2
Operating Grant: New Investigator Grants in Maternal, Reproductive, Child & Youth Health
Projecttitle
A prospective study evaluating complement activation among pregnant patients with obstetrical antiphospholipid syndrome
Programtype2
Operating Grants
Orgnameinp2
University of Calgary
Cihramount2
$104,996
Cihrequipment2
$0
Programname2
Operating Grant: ECI grants in Maternal, Reproductive, Child & Youth Health
Keyworddelim
Antiphospholipid Syndrome; Complement System; Pregnancy Complications
Abstract
Antiphospholipid syndrome (APS) is an autoimmune disease that can lead to blood clots (thrombosis) or complications in pregnancy such as pregnancy loss, pre-eclampsia or intrauterine growth restriction because of placental insufficiency. The cause of APS is poorly understood, and there is a high rate of pregnancy loss despite standard blood thinner injections and aspirin given during pregnancy. The complement system is a network of proteins and is an important part of the immune system. There is growing evidence that changes to the complement system may play a central role in what causes APS. By better understanding complement activation and which complement proteins are abnormal in pregnant patients with APS, we can research targeted therapies to improve pregnancy outcomes for women with APS.
Researchers at Johns Hopkins University have recently developed a blood test (the modified Ham test) that can detect complement activation in patients. They have already shown that there is complement activation in a related pregnancy complication called HELLP syndrome (Hemolysis, Elevated Liver enzymes, Low Platelets), and that complement activation was present before any clinical evidence of HELLP syndrome started.
The aim of our study is to assess if there is complement activation in pregnant patients with APS using the modified Ham test and other complement studies, compared to healthy pregnant women, and if this is related to pregnancy complications. We will also test if there are genetic mutations in complement genes.
We will follow pregnant patients with and without APS throughout pregnancy. We will test for complement activation with monthly blood tests until the third trimester, and then every 2 weeks until delivery. By collecting this information over time, we will determine if there is an association with the development of pregnancy complications, and if we can identify changes in complement before those complications happen.
Competitiondate
201905
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Skeith, Leslie
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $104,996~ $0~